Rapé Lab
@RapeLab
molecular mechanisms of cell fate specification in development and disease; molecular glues and induced protein degradation as new therapeutic options
A cool story presented by a true leader!
Nurix’s CSO, Gwenn M. Hansen, Ph.D., will discuss Nurix’s novel BTK degrader Bexobrutideg (NX-5948) to treat B-cell malignancies in a keynote presentation at the 3rd Targeted Protein Degradation Conference in Japan on Tuesday, July 29th at 10:35 a.m. JST. bit.ly/4jYXBBL
Tenure-track faculty search of the @Ucsf_Biochem Department is open for applications! We are looking for creative, innovative scientists asking fundamental questions in any area of biology. Join our vibrant, collaborative, and supportive community! aprecruit.ucsf.edu/JPF05702
Nurix’s Assoc. Dir. of DEL Screening Marie Lynne Malone, Ph.D., will discuss the use of DEL to develop targeted protein degradation therapies at the Gordon Research Conference on Tues, Jul 29, 2025, at 8:30 a.m. ET. Learn more: bit.ly/4kLqRgm
It’s great to see our @RapeLab paper being highlighted @CellChemBiol . Thank you @LanderLab for your comments!!
Silencing stress: Structural insights into ISR termination by the SIFI ubiquitin ligase dlvr.it/TM03Rt
So cool!
1/ Better late than never, here’s a long thread of threads summarizing our MOSAIC preprint. If you’re curious about the process by which a new microscope is conceived and brought into the world, this is the thread for you. If you’ve come for eye candy, there’s plenty of that too…
What could be more fun that connecting @UCBerkeley students and trailblazing biotechs, and hearing @CarolynBertozzi deliver an inspiring Keynote?
🚨 Bay Area Biotech Day hits @UCBerkeley next week (7/22)! Hear Nobel laureate Carolyn Bertozzi + leaders from Denali, Calico, Frontier, Nurix, Arcus & more on the next wave of drug discovery. 🧬 Posters, panels & networking. #Biotech #DrugDiscovery #UCBerkeley
New preprint w/ the Dupage lab! FSP1 KO in Tregs / Tcells promotes tumor suppression, highlighting the therapeutic value & single-agent potential of FSP1 inhibition. A new paradigm for targeting ferroptosis in the immune system (not just in cancer cells). biorxiv.org/content/10.110…
Congratulations to #MolecularTherapeutics @UCBerkeley faculty @UrnovFyodor ! And good luck 😉
A new #CRISPR Cures center, funded by $20M from @czi and led by @UrnovFyodor, will create 8 custom therapies for patients in the next 3 years. “Our goal is to aggressively walk the walk of CRISPR platformization,” Urnov told me. More in @endpts: endpoints.news/crispr-cures-c…
A new #CRISPR Cures center, funded by $20M from @czi and led by @UrnovFyodor, will create 8 custom therapies for patients in the next 3 years. “Our goal is to aggressively walk the walk of CRISPR platformization,” Urnov told me. More in @endpts: endpoints.news/crispr-cures-c…
UC Berkeley isn’t just the No. 1 public research university in the nation — it’s a force for the public good. Every discovery we make is built to serve society, from confronting climate change and improving access to clean drinking water to advancing cancer treatments and…
This paper now published in @ACSCentSci!! pubs.acs.org/doi/10.1021/ac…
Excited to highlight our latest @biorxivpreprint by graduate student @L__Orreo on the discovery of a covalent degradative handle that acts through two unique cysteines C173 and C178, on the frequent-hitting E3 ligase DCAF16 that can be used to modularly design monovalent and…
I'm honored to have been selected as a JCC postdoctoral Fellow. This will support my research in elucidating the detailed molecular mechanisms of UPR. Huge thanks to my advisors @RapeLab @aliceyting, and collaborators/colleagues for their support! jccfund.org/blog/the-jane-…
Congrats to MCB postdocs Aurora Alvarez-Buylla (Schepartz Lab), Grace Hibshman (Nogales Lab) and Heegwang Roh (Rapé Lab) for being selected as 2025 Jane Coffin Childs Fellows! 🎉👏 @schepartzlab @NogalesLab @RapeLab @heegwangroh jccfund.org/fellows/class-…
URGENT call to action: please contact any Republican senator you know to keep ORPHAN Cures Act & Accelerating Access for Kids Act in the reconciliation bill - at high risk of being removed @IAmBiotech #BIO2025
Thank you to Sara Osman for highlighting our recent SIFI work! nature.com/articles/s4159…
We are excited to present updated positive data from the ongoing Phase 1 clinical trial of bexobrutideg (NX-5948) as a monotherapy in patients with relapsed or refractory B-cell malignancies demonstrating durable and deepening responses at #EHA2025. bit.ly/403KYy3
Happy to present our latest paper with @pottslab & @Amgen in @J_A_C_S by co-first authors @C_M_Zammit & Cory Nadel on the discovery of a direct-acting covalent destabilizing degrader of AR and the undruggable truncation variant of AR, AR-V7, in androgen-independent prostate…
Happy to see our highlight out in @CurrentBiology discussing new findings related to NADH and FSP1 compartmentalization in ferroptosis. Lead by two terrific postdocs @AMegarioti and Kirandeep Deol! 🤩 cell.com/current-biolog…